Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04541537
Other study ID # IC 2020 08
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 25, 2021
Est. completion date December 20, 2021

Study information

Verified date February 2022
Source Institut Curie
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To ascertain the possibilities to isolate the breast cancer olfactive signature


Description:

Patient recruitment during the first surgery consultation in Curie Institute. Odor sampling (non-invasive) with an odor-sensing polymer (Sorbstar® polymer developed especially for the trace level analysis), on: - The hands, before and after surgical excision of the tumor (friction of the hands) - The diseased breast, before and after surgical excision of the tumor (via a compress positioned on the breast for 1 night) - The tumor, during the surgical procedure (odor collection over a tumor sample). Each patient will be her own witness, before and after surgical excision, in an attempt to isolate the chemical signature tracks of breast cancer. The samples after surgery will be made after healing and before implementation of a treatment (chemotherapy and / or radiotherapy).


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date December 20, 2021
Est. primary completion date December 9, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patient received in surgery consultation for an invasive non metastatic breast cancer treated by breast-conserving surgery with axillary or sentinel node dissection 2. Of-Age female patient (over 18 years old) 3. Life expectancy > to 1 year at the inclusion 4. ECOG performance status: 0 or 1 or 2 5. Patient benefiting from the social security 6. Signature informed consent of the study Exclusion Criteria: 1. Neoplasia in progress or neoplasia history of cancer other than breast to be treated. 2. Wound presence on breasts 3. Male subjects 4. Pregnant or lactating women 5. Specified metastatic breast cancer 6. Concomitant medication taken one month before the surgical act (antibiotics, corticoids, anti-diabetics) 7. Persons under guardianship or deprived of liberty 8. Impossibility to submit to the medical monitoring expected by the study for geographical, social or psychological reasons.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Sorbstar®
Thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry
Dog Detection
Analysed by the dogs of Curie Institute at the training centers

Locations

Country Name City State
France Institut Curie Paris

Sponsors (1)

Lead Sponsor Collaborator
Institut Curie

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary To ascertain the possibilities to isolate the breast cancer olfactive signature Isolation of volatile Organic Compounds to breast cancer by a sensitive technique with an odor-sensing polymer (Sorbstar®) on hands. Friction of the hands according to the protocol before and after surgical excision of the tumor. Sorbstar® analyses will be performed with a thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry. 18 months
Secondary Ascertain breast cancer olfactive signature from the tumor (Isolation of volatile Organic Compounds to tumor breast samples by a sensitive technique with an odor-sensing polymer (Sorbstar®) During the surgical procedure an odor-sensing polymer (Sorbstar®) over the tumor is placed. Sorbstar® analyzes will be performed with a thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry. 18 months
Secondary Ascertain breast cancer detection by the dogs of Curie Institut Patients sleep over a night with a compress positioned on the affected breast before and after surgery. The compress will be analyzed by the dogs of Curie Institut (results cancer/not cancer). 18 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A